Intuitive Surgical (NASDAQ:ISRG) experienced a sharp decline in after-hours trading on Thursday, with shares falling more than 10% despite reporting quarterly results that exceeded analyst expectations. The surgical robotics leader posted adjusted earnings per share of $2.80, surpassing the consensus forecast of $2.50-$2.51 by approximately 12%. Revenue rose 19% year-over-year to $2.892 billion, also topping estimates of $2.82-$2.83 billion.
Procedure Growth Outlook Signals Deceleration
The market's negative reaction stems from the company's decision to maintain its full-year 2026 procedure growth guidance at 13.5%-15.5%, a range it had revised upward by 0.5 percentage points in April. Preliminary calculations indicate that the midpoint of this range implies approximately 13.8% procedure growth in the second half of the year, down from 15.3% in the first half. This deceleration suggests a recalibration of future growth prospects rather than any shortfall in the latest quarter.
Intuitive Surgical's recurring revenue, which includes instruments, service, and operating leases, accounted for 85% of total revenue in Q2, reaching $2.469 billion—a 19% increase. The company performed 889,000 da Vinci procedures during the quarter, representing 15% growth year-over-year. The installed base of da Vinci systems grew 12% to 11,710 units, and the utilization rate increased by approximately 2.7%.
Leasing and System Placements Drive Revenue
Revenue growth outpaced procedure growth by three percentage points, driven by higher leasing activity and increased system placements. Operating leases accounted for 54% of da Vinci placements, up from 49% a year ago, and lease revenue jumped 22% to $261.8 million. The company also noted that da Vinci 5 installations rose 37% to 246 units, representing roughly 53% of total da Vinci system placements.
Adjusted earnings per share included a $0.08 benefit from a tariff refund. Excluding this one-time item, adjusted EPS would have been approximately $2.72, still about 8% above consensus estimates. Chief Executive Dave Rosa expressed satisfaction with the quarter's performance, highlighting strong results across da Vinci, Ion, and digital offerings.
Market Context and Risks
The medical technology sector has been under pressure amid concerns about procedure volumes, particularly after HCA Healthcare (NYSE:HCA) reported preliminary data showing a 2.3% decline in inpatient surgeries and a 3.4% drop in outpatient surgeries. Despite this, Intuitive Surgical delivered solid 15% global procedure growth in Q2. However, the steady guidance has tempered hopes for a renewed upturn.
Risks to growth include hospital budget constraints, potential insurance losses, tariffs, and emerging robotic competitors. Intuitive Surgical cautioned that additional tariffs could significantly impact its 2026 performance. The key test ahead will be third-quarter utilization, with investors looking for growth near the projected 13.8% rate or signs that management remains overly conservative.
In regular trading, Intuitive Surgical shares closed at $402.33, gaining 3.4% on the day before the after-hours selloff. The stock's decline underscores the market's focus on forward-looking guidance rather than past performance, as the company navigates a slower growth trajectory in the second half of 2026.
